BLAU3 shares rose 10.57% in the November 11 session to R$ 10.15, rebounding from a three-week slide driven by October's election-related market turmoil. The third-quarter 2026 earnings report delivered what the market wanted to see: Blau Farmacêutica posted revenue above R$ 500 million for the first time in company history alongside expanding margins. However, the headline accounting profit still unnerves investors unfamiliar with the details.
Why Was BLAU3 Falling?
The sell-off stemmed from two main roots. The first is macroeconomic: on October 26, 2026, the Ibovespa plunged 13.88% and triggered a circuit breaker immediately following President Lula's reelection. BLAU3 shares fell even harder, dropping 21.33% in a single session from R$ 12.33 to R$ 9.70. With a free float of just 16.55%—well below the 25% minimum required by B3's Novo Mercado segment—the stock amplifies sharp moves. During generalized panic, sellers find fewer buyers on the other side. Low-liquidity stocks bleed more during macro shocks, regardless of their fundamentals.
The second root is operational. In the second quarter of 2026, Blau posted an accounting profit of R$ 56 million, down 12%, while revenue grew just 5%, a noticeable deceleration from the first quarter's 17% growth. The private-sector segment had contracted, and the company made a disciplined choice to tighten credit for distributors, which reined in short-term billing. Two compressed quarters on a thinly traded stock is a combination that spooks margin-focused investors.
What Q3 2026 Revealed
Blau Farmacêutica reported net revenue of R$ 506 million in the third quarter, up 7% year-over-year. This marks the first time a single quarter crossed the half-billion-real threshold. More important than the headline figure is where the growth came from: the public-sector segment more than doubled compared to Q3 2025, reversing the second-quarter decline, while exports to Latin America rose 24% to account for 9% of total revenue.
+7% YoY — historic milestone, first quarter above R$ 500 million.
+7% YoY — excludes currency fluctuations and non-recurring items.
+1.2 percentage points vs. Q3 2025 — highest margin of the year.
Recurring EBITDA reached R$ 128 million (+12%), but the gross margin expansion drew the most attention, climbing to 43.2%—a 2.6 percentage point gain over the same period in 2025. According to the company, this improvement did not stem from price hikes, but rather from industrial efficiency, fixed-cost dilution, and a more favorable product mix. Cash generation also surprised: operating cash flow rose 59% to R$ 228 million, and free cash totaled R$ 88 million—3.4 times the volume seen in Q3 2025. The company closed September with R$ 1 billion in cash and a net debt-to-EBITDA ratio of -0.2x, meaning cash exceeded gross debt by approximately R$ 98 million.
The Profit the Headline Misses
Investors who reviewed the earnings report without context saw an accounting net profit of R$ 69 million—down 34.6% from R$ 105.5 million in Q3 2025—and may have found the stock's rise puzzling. The issue lies in the comparison: a year ago, Blau posted a positive financial result of R$ 46.7 million, inflated by a gain from selling its stake in Prothya, a one-off event that does not repeat. In Q3 2026, the financial result was negative by R$ 20.4 million, creating a R$ 67 million swing between the two periods. Operations improved, but the stock received no credit because the 2025 comparison was atypically favorable.
Recurring profit is the lens the market used to price the session: operations grew, margins improved, and cash generation accelerated. For investors entering the stock seeking operational growth, Q3 2026 confirms that the problem was the environment, not the company. Raia Drogasil's results for the same quarter also beat expectations, signaling that Brazil's pharmaceutical sector continues to deliver despite macro headwinds.
What Still Separates Blau from a Full Growth Thesis
While Q3 2026 was solid, it did not erase the market's lingering reservations. The private hospital segment fell 12% compared to Q3 2025, and it remains the company's largest revenue block. The recovery came from public and international segments, which follow different dynamics: government procurement is more volatile, and internationalization still accounts for only 9% of revenue. Until the private sector resumes consistent growth, the acceleration thesis remains unconfirmed.
The free float issue has not disappeared either. With 16.55% of shares in free circulation—versus the 25% required by the Novo Mercado—B3 extended the compliance deadline from December 2026 to December 31, 2027. However, the controlling shareholder has not ruled out the possibility of delisting and pursuing a U.S. listing in recent interviews. Should that move forward, current investors will face a tender offer (OPA) with a price set by the company, not the market.
- Quarterly revenue above R$ 500 million for the first time — a structural milestone in company scale.
- Recurring EBITDA margin at 25.3%, the year's highest, with expansion driven by efficiency rather than pricing.
- Net cash positive at approximately R$ 98 million — gross debt is lower than cash reserves.
- Operating cash flow rose 59%; free cash flow stands at 3.4 times the Q3 2025 level.
- Latin American exports rose 24%; biosimilar pipeline under development.
- Private hospital segment fell 12% YoY — the largest revenue block has not yet recovered.
- Free float stands at 16.55%; the controlling shareholder has not ruled out delisting and listing in the U.S.
- Accounting profit down 34.6% — the Q3 2025 comparative base will continue to pressure headline figures in Q4 2026.
Research and development investments totaled R$ 140 million in the quarter (+19%), concentrated in biosimilars—particularly pembrolizumab, a standard treatment for several types of cancer, with a launch scheduled for 2028 following the expiration of the reference product's patent. Fleury also posted solid earnings in the healthcare sector this quarter, reinforcing that pressure on Blau stemmed more from election-related shocks and comparative bases than from sector deterioration.
What to Monitor in Coming Quarters
Today's market turnaround is real, but the continuous growth thesis still depends on catalysts that Q3 2026 did not deliver. Other healthcare stocks like ALOS3 confirmed dividends and more robust growth this month, while Blau still needs to prove in the private segment that its Q3 recovery was not a one-off event.
Private Sector Recovery in Q4 2026 — the largest block of hospital revenue fell 12% in the third quarter. Growth above zero in the next earnings report would confirm that the credit tightening in Q2 2026 was a tactical decision, not a sign of structural market share loss.
Free Float Decision by December 31, 2027 — will the controller sell shares to reach the 25% threshold, or propose a delisting? A buyout offer alters the investment profile from growth to forced liquidity at a tender offer price.
Q4 2026 Comparative Base — the Prothya gain did not exist in Q4 2025, meaning financial comparison pressure will ease. If accounting profit converges with recurring profit in the fourth quarter, the noise that confused the market over the past two quarters will disappear.
Biosimilar Pipeline — with R$ 140 million invested in R&D this quarter, the launch of the pembrolizumab biosimilar is projected for 2028. Updates on regulatory approvals and market entry timelines will determine whether this investment translates into revenue within a relevant timeframe for today's shareholders.
